Reducing polycystic liver volume in ADPKD: Effects of somatostatin analogue octreotide

Anna Caroli, Luca Antiga, Mariateresa Cafaro, Giorgio Fasolini, Andrea Remuzzi, Giuseppe Remuzzi, Piero Ruggenenti

Research output: Contribution to journalArticle

91 Citations (Scopus)

Abstract

Background and objectives: No medical treatment is available for polycystic liver disease, a frequent manifestation of autosomal-dominant polycystic kidney disease (ADPKD). In a prospective, randomized, double-blind, crossover study, 6 months of octreotide (40 mg every 28 days) therapy limited kidney volume growth more effectively than placebo in 12 patients with ADPKD. Design, setting, participants, & measurements: In this secondary, post hoc analysis of the above study, octreotide-induced changes in liver volumes compared with placebo and the relationship between concomitant changes in liver and kidney volumes were evaluated. Those analyzing liver and kidney volumes were blinded to treatment. Results: Liver volumes significantly decreased from 1595 ± 478 ml to 1524 ± 453 ml with octreotide whereas they did not appreciably change with placebo. Changes in liver volumes were significantly different between the two treatment periods (-71 ± 57 ml versus +14 ± 85 ml). Octreotide-induced liver volume reduction was fully explained by a reduction in parenchyma volume from 1506 ± 431 ml to 1432 ± 403 ml. Changes in liver volumes were significantly correlated with concomitant changes in kidney volumes (r = 0.67) during octreotide but not during placebo treatment. Liver and kidney volume changes significantly differed with both treatments (octreotide: -71 ± 57 ml versus +71 ± 107; placebo: +14 ± 85 ml versus +162 ± 114), but net reductions in liver (-85 ± 103 ml) and kidney (-91 ± 125 ml) volume growth on octreotide versus placebo were similar. Conclusions: Octreotide therapy reduces liver volumes in patients with ADPKD and is safe.

Original languageEnglish
Pages (from-to)783-789
Number of pages7
JournalClinical Journal of the American Society of Nephrology
Volume5
Issue number5
DOIs
Publication statusPublished - May 1 2010

Fingerprint

Autosomal Dominant Polycystic Kidney
Octreotide
Somatostatin
Liver
Placebos
Kidney
Therapeutics
Growth
Double-Blind Method
Cross-Over Studies

ASJC Scopus subject areas

  • Nephrology
  • Transplantation
  • Epidemiology
  • Critical Care and Intensive Care Medicine

Cite this

Reducing polycystic liver volume in ADPKD : Effects of somatostatin analogue octreotide. / Caroli, Anna; Antiga, Luca; Cafaro, Mariateresa; Fasolini, Giorgio; Remuzzi, Andrea; Remuzzi, Giuseppe; Ruggenenti, Piero.

In: Clinical Journal of the American Society of Nephrology, Vol. 5, No. 5, 01.05.2010, p. 783-789.

Research output: Contribution to journalArticle

Caroli, Anna ; Antiga, Luca ; Cafaro, Mariateresa ; Fasolini, Giorgio ; Remuzzi, Andrea ; Remuzzi, Giuseppe ; Ruggenenti, Piero. / Reducing polycystic liver volume in ADPKD : Effects of somatostatin analogue octreotide. In: Clinical Journal of the American Society of Nephrology. 2010 ; Vol. 5, No. 5. pp. 783-789.
@article{9bf3b712dd714d69819d3a4e7af309a7,
title = "Reducing polycystic liver volume in ADPKD: Effects of somatostatin analogue octreotide",
abstract = "Background and objectives: No medical treatment is available for polycystic liver disease, a frequent manifestation of autosomal-dominant polycystic kidney disease (ADPKD). In a prospective, randomized, double-blind, crossover study, 6 months of octreotide (40 mg every 28 days) therapy limited kidney volume growth more effectively than placebo in 12 patients with ADPKD. Design, setting, participants, & measurements: In this secondary, post hoc analysis of the above study, octreotide-induced changes in liver volumes compared with placebo and the relationship between concomitant changes in liver and kidney volumes were evaluated. Those analyzing liver and kidney volumes were blinded to treatment. Results: Liver volumes significantly decreased from 1595 ± 478 ml to 1524 ± 453 ml with octreotide whereas they did not appreciably change with placebo. Changes in liver volumes were significantly different between the two treatment periods (-71 ± 57 ml versus +14 ± 85 ml). Octreotide-induced liver volume reduction was fully explained by a reduction in parenchyma volume from 1506 ± 431 ml to 1432 ± 403 ml. Changes in liver volumes were significantly correlated with concomitant changes in kidney volumes (r = 0.67) during octreotide but not during placebo treatment. Liver and kidney volume changes significantly differed with both treatments (octreotide: -71 ± 57 ml versus +71 ± 107; placebo: +14 ± 85 ml versus +162 ± 114), but net reductions in liver (-85 ± 103 ml) and kidney (-91 ± 125 ml) volume growth on octreotide versus placebo were similar. Conclusions: Octreotide therapy reduces liver volumes in patients with ADPKD and is safe.",
author = "Anna Caroli and Luca Antiga and Mariateresa Cafaro and Giorgio Fasolini and Andrea Remuzzi and Giuseppe Remuzzi and Piero Ruggenenti",
year = "2010",
month = "5",
day = "1",
doi = "10.2215/CJN.05380709",
language = "English",
volume = "5",
pages = "783--789",
journal = "Clinical journal of the American Society of Nephrology : CJASN",
issn = "1555-9041",
publisher = "by the American Society of Nephrology",
number = "5",

}

TY - JOUR

T1 - Reducing polycystic liver volume in ADPKD

T2 - Effects of somatostatin analogue octreotide

AU - Caroli, Anna

AU - Antiga, Luca

AU - Cafaro, Mariateresa

AU - Fasolini, Giorgio

AU - Remuzzi, Andrea

AU - Remuzzi, Giuseppe

AU - Ruggenenti, Piero

PY - 2010/5/1

Y1 - 2010/5/1

N2 - Background and objectives: No medical treatment is available for polycystic liver disease, a frequent manifestation of autosomal-dominant polycystic kidney disease (ADPKD). In a prospective, randomized, double-blind, crossover study, 6 months of octreotide (40 mg every 28 days) therapy limited kidney volume growth more effectively than placebo in 12 patients with ADPKD. Design, setting, participants, & measurements: In this secondary, post hoc analysis of the above study, octreotide-induced changes in liver volumes compared with placebo and the relationship between concomitant changes in liver and kidney volumes were evaluated. Those analyzing liver and kidney volumes were blinded to treatment. Results: Liver volumes significantly decreased from 1595 ± 478 ml to 1524 ± 453 ml with octreotide whereas they did not appreciably change with placebo. Changes in liver volumes were significantly different between the two treatment periods (-71 ± 57 ml versus +14 ± 85 ml). Octreotide-induced liver volume reduction was fully explained by a reduction in parenchyma volume from 1506 ± 431 ml to 1432 ± 403 ml. Changes in liver volumes were significantly correlated with concomitant changes in kidney volumes (r = 0.67) during octreotide but not during placebo treatment. Liver and kidney volume changes significantly differed with both treatments (octreotide: -71 ± 57 ml versus +71 ± 107; placebo: +14 ± 85 ml versus +162 ± 114), but net reductions in liver (-85 ± 103 ml) and kidney (-91 ± 125 ml) volume growth on octreotide versus placebo were similar. Conclusions: Octreotide therapy reduces liver volumes in patients with ADPKD and is safe.

AB - Background and objectives: No medical treatment is available for polycystic liver disease, a frequent manifestation of autosomal-dominant polycystic kidney disease (ADPKD). In a prospective, randomized, double-blind, crossover study, 6 months of octreotide (40 mg every 28 days) therapy limited kidney volume growth more effectively than placebo in 12 patients with ADPKD. Design, setting, participants, & measurements: In this secondary, post hoc analysis of the above study, octreotide-induced changes in liver volumes compared with placebo and the relationship between concomitant changes in liver and kidney volumes were evaluated. Those analyzing liver and kidney volumes were blinded to treatment. Results: Liver volumes significantly decreased from 1595 ± 478 ml to 1524 ± 453 ml with octreotide whereas they did not appreciably change with placebo. Changes in liver volumes were significantly different between the two treatment periods (-71 ± 57 ml versus +14 ± 85 ml). Octreotide-induced liver volume reduction was fully explained by a reduction in parenchyma volume from 1506 ± 431 ml to 1432 ± 403 ml. Changes in liver volumes were significantly correlated with concomitant changes in kidney volumes (r = 0.67) during octreotide but not during placebo treatment. Liver and kidney volume changes significantly differed with both treatments (octreotide: -71 ± 57 ml versus +71 ± 107; placebo: +14 ± 85 ml versus +162 ± 114), but net reductions in liver (-85 ± 103 ml) and kidney (-91 ± 125 ml) volume growth on octreotide versus placebo were similar. Conclusions: Octreotide therapy reduces liver volumes in patients with ADPKD and is safe.

UR - http://www.scopus.com/inward/record.url?scp=77952318861&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952318861&partnerID=8YFLogxK

U2 - 10.2215/CJN.05380709

DO - 10.2215/CJN.05380709

M3 - Article

C2 - 20185596

AN - SCOPUS:77952318861

VL - 5

SP - 783

EP - 789

JO - Clinical journal of the American Society of Nephrology : CJASN

JF - Clinical journal of the American Society of Nephrology : CJASN

SN - 1555-9041

IS - 5

ER -